Can Red Light Therapy Affect Blood Clotting?

A clot is one of the body’s best repairs and one of its costliest mistakes. When a vessel tears, blood has to seal the gap within moments. When a clot forms inside an intact vessel, the same response can block blood flow to the lungs, the brain, or the heart.

That balance is why a surprising variable has caught researchers’ attention: light. In a 2025 study in the Journal of Thrombosis and Haemostasis, mice kept under red light for 72 hours developed venous clots less than a quarter the weight of those in mice under white light. A 2026 commentary in Seminars in Thrombosis and Hemostasis by Fan and colleagues then gathered the wider photobiomodulation (PBM) literature on how red and near-infrared light affect platelets, the lining of blood vessels, and the immune signals that feed into clotting.

So where does red light therapy and blood clotting stand today? Light can change platelet behavior in laboratory and animal settings. A room lit red, a laser aimed at a blood sample, and a panel on the skin are three different interventions, though, and each result applies only to the one that was tested.

A damaged blood vessel immediately launches hemostasis, the body's system for stopping bleeding. The first response is mechanical. The vessel wall constricts to slow the flow while platelets, the small cell fragments circulating in blood, rush to the injury. They stick to the exposed surface, change shape, and release chemical signals that call in more platelets. This clumping is called platelet aggregation, and it builds a temporary plug. 

The plug alone would not hold for long. Damage also switches on the coagulation cascade, a chain of reactions among clotting factors in the blood plasma that ends with an enzyme called thrombin. Thrombin converts fibrinogen, a soluble protein, into fibrin. Strands of fibrin weave through the platelet plug like mesh and lock it into a stable clot. Once the vessel heals, fibrinolysis breaks the fibrin down and clears the clot away.

Thrombosis is the same machinery running in the wrong place. A thrombus forms inside a vessel, often where blood flow is slow or the vessel lining is inflamed or injured, and it can narrow or block the vessel. In the veins, this produces deep vein thrombosis (DVT). A fragment that breaks loose and lodges in the lungs causes pulmonary embolism, and the two conditions together are known as venous thromboembolism (VTE). In the arteries, a clot can cut off blood to the brain or heart and cause a stroke or heart attack.

Platelets and fibrin do the same job in a cut finger and in a blocked vein. Researchers studying light have started with the platelets, and with the immune signals that recruit them.

PBM uses red and near-infrared light to trigger biological responses. Cells contain light-absorbing molecules, including enzymes in the mitochondria, and absorbing that light can shift energy production and cell signaling. For clotting, researchers have looked in three places: the vessel lining, where nitric oxide signaling sets the tone for the vessel and the platelets passing through it; the platelets themselves; and the immune cells that amplify a clot once platelets activate. Fan and colleagues note that these effects align with Virchow’s triad, the three classic conditions that favor thrombosis: a damaged vessel lining, sluggish blood flow, and blood chemistry tilted toward clotting.

The endothelium is the thin layer of cells lining every blood vessel. It releases nitric oxide (NO), a signaling molecule that relaxes the vessel wall, widens the vessel, and discourages platelets from sticking. Light can influence this pathway. Wajih and colleagues found that far-red light enhanced NO signaling from red blood cells primed with nitrite, a compound the cells convert into NO. The same system underlies the interest in red light therapy and blood pressure, where vessel relaxation is the central question.

Wider vessels and stronger microcirculation, the flow through the smallest vessels, describe how blood moves. They don’t describe how readily blood clots, so evidence for one doesn’t carry over to the other.

Platelet activation is the switch that turns a resting platelet into a sticky, shape-shifted one that signals its neighbors, and aggregation is the clumping that follows. A platelet that is harder to activate gives a clot less to build on.

Does red light therapy thin your blood? Not in the way medication does. Anticoagulants slow the coagulation cascade, while the light studies measured platelet behavior and clot size in experimental models. None established a blood-thinning effect from a red light device.

Von Willebrand factor (vWF) is a large protein made by endothelial cells and platelets. When a vessel wall is damaged, vWF unfurls and catches passing platelets, working a bit like molecular Velcro to anchor them at the injury. Fan and colleagues point to experimental data suggesting PBM may reduce vWF activity, which would weaken that first attachment.

Thromboinflammation describes the interplay between immune cells, platelets, and coagulation. Neutrophils, a frontline immune cell, can cast out web-like structures of DNA and protein called neutrophil extracellular traps (NETs). NETs normally trap microbes, but in thrombosis they also capture platelets and give a growing clot scaffolding. Because NETs sit where immunity meets clotting, they have become a focus of experimental thrombosis research, and they are the thread that connects the light studies in the next section.

Red light can alter how platelets behave before a clot forms. Laboratory and animal studies report reduced platelet activation and aggregation after red light exposure, and mice exposed to red light developed smaller experimental clots. Even so, research has not established that localized red light therapy can prevent or treat blood clots in people.

A 2026 commentary by Fan and colleagues in Seminars in Thrombosis and Hemostasis reviews experimental data across red, near-infrared, and far-infrared photobiomodulation. Their synthesis highlights three main takeaways for clotting research:

• Vascular and platelet effects: Experimental models suggest PBM influences nitric oxide release, endothelial function, and vascular tone. Data also point to reduced platelet aggregation and lower von Willebrand factor activity alongside improved microvascular perfusion.

• Key research limitations: Light penetrates human tissue only to a shallow depth, study protocols vary widely across labs, and translating animal or bench findings into clinical practice remains difficult.

• The blue-light question: Researchers still do not know whether clot-related shifts come from red and near-infrared light acting directly on cells, or simply from removing blue light, which the authors describe as pro-thrombotic.

Fan and colleagues note that light-based approaches could eventually warrant study in patients whose bleeding risk complicates standard blood thinners. For now, that idea stays strictly inside the lab, not as an established alternative to anticoagulant medication.

The most direct clotting data comes from a University of Pittsburgh team published in the Journal of Thrombosis and Haemostasis. Researchers housed mice under three lighting conditions for 72 hours (on a 12-hour light/dark cycle) before inducing clots:

Why platelets behaved differently

• Lower reactivity: Platelets from red-light mice reacted less to collagen and ADP (two standard clotting triggers) and carried fewer surface activation markers.

• Reduced immune amplification: Their clots contained fewer neutrophil extracellular traps (NETs). Signals secreted by red-light platelets triggered less NET formation in neutrophils, even though the neutrophils themselves functioned normally—pinpointing the shift to the platelets.

• Metabolic changes: Red-light platelets showed higher levels of oleic and linoleic acid, fatty acids known to dampen platelet activity.

Critical caveats for real-world red light devices

• Timing mattered: Red light protected mice only when exposure happened before clot-inducing surgery, not after.

• The effect worked through the eyes, not the skin: Genetically blind mice showed no difference across red, white, or blue light, and human platelets exposed directly to red light in a lab dish behaved no differently than platelets under ambient light. Because this model relied on intact vision responding to room lighting, it was not a test of a localized light therapy device treating tissue.

The human cataract cohort (10,464 patients)The team also tracked 10,464 cataract surgery patients over a median of 5.1 years, comparing 7,035 patients who received blue-light-filtering lenses against 3,429 who received standard lenses:

• Overall group: Filtering lenses showed a slight trend toward lower VTE risk, though the result was not statistically significant (adjusted hazard ratio 0.91, 95% CI 0.61 to 1.36).

• Patients with a cancer history: In this higher-risk subgroup, blue-light-filtering lenses were linked to significantly lower VTE risk (adjusted hazard ratio 0.53, 95% CI 0.33 to 0.83).

Because these lenses block blue light rather than add red light, the authors note that their findings cannot separate whether red light actively reduces clots or whether removing blue light simply removes a clot-promoting trigger.

Unlike the mouse lighting study, Rola and colleagues applied laser light directly to human blood samples in a two-stage lab experiment: an initial dose-response test with nine volunteers, followed by a larger trial with 41 healthy participants aged 21 to 45.

• The setup and result: Using the optimal dose from stage one (~19.8 J/cm²) and a 662 nm laser, researchers saw platelet aggregation drop in response to three triggers: ADP, collagen, and a thrombin-receptor agonist.

• The surprise mechanism: The team expected nitric oxide to drive the change, yet nitric oxide pathway metabolites, platelet factor 4, and soluble P-selectin all stayed flat. Whatever slowed platelet clumping worked through a different, unconfirmed pathway.

• Key limitations: Because this was an in vitro test on blood drawn from healthy volunteers, it does not show reduced thrombosis inside a living patient.

• Wavelength and dose sensitivity: Laser effects on platelets are far from uniform. An older argon laser experiment (Doerger et al., 1988) found that low irradiation actually increased platelet aggregation while high irradiation destroyed platelets, underscoring how heavily wavelength and dose dictate the outcome.

A research team at Wake Forest University took a combination approach, pairing 660 nm far-red light with nitrite, a compound the body can convert into nitric oxide (NO) under specific biological conditions.

• 2019 initial study: Five minutes of 660 nm light boosted the ability of red blood cells to convert nitrite into NO. This strengthened nitrite's inhibition of human platelet activation and lengthened clotting lag time in plasma.

• 2021 follow-up testing: Researchers tested the combination on human platelet-rich plasma and whole blood across four lab methods (turbidity assays, flow cytometry, impedance aggregometry, and platelet adhesion to collagen). The pairing lowered coagulation measures across every test.

• Importance of the Pairing: Nitrite alone or light alone sometimes produced no effect, and platelet adhesion results for either treatment by itself were mixed. The anti-clotting effect depended on combining both, not on far-red light acting alone.

• Practical limits: Because light only penetrates shallow tissue, the authors note that the clearest fit for this approach is in extracorporeal blood circuits (such as dialysis or bypass equipment) or shallow-tissue medical devices rather than deep internal clots.

Platelets have drawn most of the attention in light therapy research because standard coagulation and clot-breakdown markers barely budge on their own. In the Andraska et al. mouse model, prothrombin time, partial thromboplastin time, and INR showed no difference across lighting groups. Fibrinolysis markers (D-dimer and PAI-1), tail bleeding time, and fibrinogen deposition inside the clots also stayed flat, confirming that smaller clots stemmed from platelet and NET shifts rather than changes in the clotting cascade or clot-dissolving speed.

Direct shifts in coagulation measurements appear only when far-red light is paired with added nitrite. In Wajih et al.'s in vitro studies, that combination lengthened clotting lag time in platelet-poor plasma (2019) and lowered coagulation measures in platelet-rich plasma (2021), though neither result occurred from light alone. Evidence around von Willebrand factor (vWF) is similarly indirect: while Fan et al. note experimental data suggesting lower vWF activity, Andraska's team tracked vWF strictly as a platelet activation marker rather than running a direct functional test of vWF itself.

Direct effects on thrombin generation and fibrinolysis remain open questions. Across current studies, the clearest biological signal sits with platelets, while data elsewhere in the clotting cascade remain limited and model-specific.

Thrombosis research centers on the exact biological targets measured in light studies: platelets, the vessel lining, and the inflammatory signals linking them. Because NET-driven inflammation and platelet activation drive clots across different parts of the circulatory system, the University of Pittsburgh mouse findings span both venous clots (modeling DVT and pulmonary embolism) and arterial clots (modeling stroke). In both models, pre-exposure to red light reduced clot burden or brain injury.

Crucially, those experiments tested prevention before an injury, not treatment for a clot that had already formed. Once a clot was induced, red light exposure made no meaningful difference. To explore whether this eye-mediated mechanism translates to humans, the Pittsburgh researchers are developing specialized red-light goggles for upcoming trials in high-risk patients. Until those clinical trials produce results, this remains an early research concept rather than a clinical option.

While clinical researchers continue investigating how specific light protocols interact with vascular biology, localized consumer PBM devices remain focused on general circulation, cellular energy, and tissue recovery. Current evidence comes from experimental setups rather than standard home use, meaning red light therapy is not a method to prevent or dissolve existing blood clots and should never replace prescribed blood thinners.

Current clinical research has not tested photobiomodulation devices in people taking anticoagulants or antiplatelet medications, so safety in those groups remains unstudied. Anyone using blood thinners, or living with a clotting or bleeding condition, should consult their physician before adding red light therapy to a routine.

This precaution comes down to overlapping biological pathways. Anticoagulants such as warfarin and direct oral anticoagulants slow the clotting cascade, while antiplatelet drugs like aspirin dampen platelet activity. Because light exposure altered platelet behavior in the laboratory and animal studies above, researchers have not yet mapped how the two might interact in a person. The same caution applies to people with bleeding disorders, a history of DVT, pulmonary embolism, or arterial thrombosis, and anyone currently undergoing treatment for a clotting condition.

At the same time, these studies do not prove that consumer red light panels are unsafe for those groups. Experimental setups using room-level mouse lighting, direct laser blood irradiation, and light-plus-nitrite chemistry differ substantially from shining a panel on the skin. The specific combination with blood-thinning medication simply lacks human safety data, making a prescribing physician the best person to weigh individual risk.

Before light-based protocols can move from experimental models into clinical vascular care, researchers have three major variables to map:

• Wavelength: Positive shifts appeared with 617 nm environmental light, 662 nm laser light, and 660 nm far-red light, leaving open whether other red and near-infrared wavelengths produce the same effect.

• Dose and schedule: Rola’s team saw the strongest response at 19.8 J/cm², yet optimal irradiance, exposure duration, and treatment schedules still need systematic testing.

• Direct red light effects: As both Fan and Andraska note, studies still need to isolate whether red light actively lowers clotting risk on its own or whether those shifts stem partly from filtering out shorter wavelengths like blue light.

The biggest hurdle is translating these experimental setups into real-world human use. Andraska’s protective effect worked through the eyes, Rola’s relied on a laser aimed at drawn blood in a lab, and Wajih’s depended on added nitrite. None mirrors a localized panel treating a limb or torso, and future human clinical trials will need to prove that shifts in platelet lab markers actually result in fewer clots in patients.

Current research shows that red light can influence platelet behavior under controlled experimental conditions. What remains to be seen is whether those cellular effects can be reproduced safely and reliably in people using practical light-based therapies.

1. Fan BE, Pasalic L, Hew YY, Lippi G, Favaloro EJ. Red light therapy in thrombosis and hemostasis. Semin Thromb Hemost. 2026;52(2):266-272. doi:10.1055/a-2717-5157 (published as a Commentary; online October 2025)

2. Andraska EA, Denorme F, Kaltenmeier C, et al. Alterations in visible light exposure modulate platelet function and regulate thrombus formation. J Thromb Haemost. 2025;23(1):123-138. doi:10.1016/j.jtha.2024.08.020

3. Rola P, Doroszko A, Szahidewicz-Krupska E, et al. Low-level laser irradiation exerts antiaggregative effect on human platelets independently on the nitric oxide metabolism and release of platelet activation markers. Oxid Med Cell Longev. 2017;2017:6201797. doi:10.1155/2017/6201797

4. Wajih N, Alipour E, Rigal F, et al. Effects of nitrite and far-red light on coagulation. Nitric Oxide. 2021;107:11-18. doi:10.1016/j.niox.2020.11.005. PMID: 33271226

5. Wajih N, et al. Erythrocytic bioactivation of nitrite and its potentiation by far-red light. Redox Biol. 2019;20:442-450. doi:10.1016/j.redox.2018.11.001

6. Doerger PT, Glueck HI, McGill M. The effects of argon laser on in vitro aggregation of platelets in platelet rich plasma and whole blood. Thromb Res. 1988;50(5). (read in abstract only)

7. Centers for Disease Control and Prevention. About venous thromboembolism (blood clots). https://www.cdc.gov/blood-clots/about/